{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T08:31:04Z","timestamp":1786523464920,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"STER Internationalisation of Doctoral Schools Programme of the Polish National Agency for Academic Exchange","award":["PPI\/STE\/2020\/1\/00014\/DEC\/02"],"award-info":[{"award-number":["PPI\/STE\/2020\/1\/00014\/DEC\/02"]}]},{"DOI":"10.13039\/501100001870","name":"Fundacja na rzecz Nauki Polskiej","doi-asserted-by":"publisher","award":["FENG.02.02-IP.05-0361\/23"],"award-info":[{"award-number":["FENG.02.02-IP.05-0361\/23"]}],"id":[{"id":"10.13039\/501100001870","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"DOI":"10.1007\/s43440-026-00888-w","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T07:52:57Z","timestamp":1786521177000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The course of platinum-based chemotherapy is associated with the risk of hematological complications during poly(ADP-ribose) polymerase (PARP) inhibitor therapy in patients with ovarian cancer"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1933-7530","authenticated-orcid":false,"given":"Cezary","family":"Miedziarek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4144-7706","authenticated-orcid":false,"given":"Aleksandra","family":"G\u0142adych-Macioszek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Potograbski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Kap\u0142on","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Nowak-Markwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4400-6688","authenticated-orcid":false,"given":"Miko\u0142aj Piotr","family":"Zaborowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"888_CR1","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s11523-023-00970-w","volume":"18","author":"DM O\u2019Malley","year":"2023","unstructured":"O\u2019Malley DM, Krivak TC, Kabil N, Munley J, Moore KN. PARP Inhibitors in Ovarian Cancer: A Review. Target Oncol. 2023;18:471\u2013503. https:\/\/doi.org\/10.1007\/s11523-023-00970-w.","journal-title":"Target Oncol"},{"key":"888_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2018.12.002","volume":"73","author":"E Franzese","year":"2019","unstructured":"Franzese E, Centonze S, Diana A, Carlino F, Guerrera LP, Di Napoli M, et al. PARP inhibitors in ovarian cancer. Cancer Treat Rev. 2019;73:1\u20139. https:\/\/doi.org\/10.1016\/j.ctrv.2018.12.002.","journal-title":"Cancer Treat Rev"},{"key":"888_CR3","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13048-024-01362-y","volume":"17","author":"I Barad\u00e1cs","year":"2024","unstructured":"Barad\u00e1cs I, Teutsch B, V\u00e1radi A, Bil\u00e1 A, Vincze \u00c1, Hegyi P, et al. PARP inhibitor era in ovarian cancer treatment: a systematic review and meta-analysis of randomized controlled trials. J Ovarian Res. 2024;17:53. https:\/\/doi.org\/10.1186\/s13048-024-01362-y.","journal-title":"J Ovarian Res"},{"key":"888_CR4","doi-asserted-by":"publisher","first-page":"8125","DOI":"10.3390\/ijms23158125","volume":"23","author":"C-H Lau","year":"2022","unstructured":"Lau C-H, Seow K-M, Chen K-H. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review. Int J Mol Sci. 2022;23:8125. https:\/\/doi.org\/10.3390\/ijms23158125.","journal-title":"Int J Mol Sci"},{"key":"888_CR5","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","volume":"20","author":"CJ LaFargue","year":"2019","unstructured":"LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol. 2019;20:e15\u201328. https:\/\/doi.org\/10.1016\/S1470-2045(18)30786-1.","journal-title":"Lancet Oncol"},{"key":"888_CR6","doi-asserted-by":"publisher","first-page":"e390876","DOI":"10.1200\/EDBK_390876","volume":"43","author":"M Friedlander","year":"2023","unstructured":"Friedlander M, Lee YC, Tew WP. Managing Adverse Effects Associated With Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer: A Synthesis of Clinical Trial and Real-World Data. Am Soc Clin Oncol Educ Book. 2023;43:e390876. https:\/\/doi.org\/10.1200\/EDBK_390876.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"888_CR7","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1177\/1078155218800156","volume":"25","author":"NS Patibandla","year":"2019","unstructured":"Patibandla NS, Monga DK. Niraparib - A promising drug with hematological toxicity. J Oncol Pharm Pract. 2019;25:1749\u201353. https:\/\/doi.org\/10.1177\/1078155218800156.","journal-title":"J Oncol Pharm Pract"},{"key":"888_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ph18040528","author":"D Speranza","year":"2025","unstructured":"Speranza D, Omero F, Cianci V, Marafioti M, Infurna C, Carroccio P, et al. Pharmaceuticals multidisciplinary digit publishing Inst. 2025;18:528. https:\/\/doi.org\/10.3390\/ph18040528. Comparison Study of the Safety Profile of Olaparib Versus Niraparib: Analysis of Real-World Data from EudraVigilance."},{"key":"888_CR9","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ejogrb.2024.12.021","volume":"305","author":"MF Pio Maiorano","year":"2025","unstructured":"Pio Maiorano MF, Loizzi V, Maiorano BA, Cormio G. Haematological toxicity of PARP inhibitors in advanced ovarian cancer: A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2025;305:232\u201340. https:\/\/doi.org\/10.1016\/j.ejogrb.2024.12.021.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"888_CR10","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1136\/ijgc-2022-004079","volume":"33","author":"BJ Monk","year":"2023","unstructured":"Monk BJ, Gonz\u00e1lez-Mart\u00edn A, Buckley L, Matulonis UA, Rimel BJ, Wu X, et al. Safety and management of niraparib monotherapy in ovarian cancer clinical trials. Int J Gynecol Cancer. 2023;33:971\u201381. https:\/\/doi.org\/10.1136\/ijgc-2022-004079.","journal-title":"Int J Gynecol Cancer"},{"key":"888_CR11","doi-asserted-by":"publisher","unstructured":"Zhou Y, Zhao S, Wu T, Zhang H. Comparison of adverse reactions caused by olaparib for different indications. Front Pharmacol [Internet]. Frontiers; 2022 [cytowane 6 lipca 2026];13. https:\/\/doi.org\/10.3389\/fphar.2022.968163","DOI":"10.3389\/fphar.2022.968163"},{"key":"888_CR12","doi-asserted-by":"publisher","first-page":"e34123","DOI":"10.1097\/MD.0000000000034123","volume":"102","author":"C Shiraishi","year":"2023","unstructured":"Shiraishi C, Hirai T, Kaneda M, Okamoto A, Kato H, Tanaka K, et al. Factors for the development of anemia in patients with newly introduced olaparib: A retrospective case-control study. Med (Baltim). 2023;102:e34123. https:\/\/doi.org\/10.1097\/MD.0000000000034123.","journal-title":"Med (Baltim)"},{"key":"888_CR13","doi-asserted-by":"publisher","unstructured":"Jagannathan-Bogdan M, Zon LI. Hematopoiesis. Development. Vol 140. Cambridge, England;2013. pp. 2463\u20137. https:\/\/doi.org\/10.1242\/dev.083147.","DOI":"10.1242\/dev.083147"},{"key":"888_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.898150","author":"R Tashiro","year":"2022","unstructured":"Tashiro R, Kawazoe H, Mamishin K, Seto K, Udagawa R, Saito Y, et al. Patient-associated risk factors for severe anemia in patients with advanced ovarian or breast cancer receiving olaparib monotherapy: A multicenter retrospective study. Front Oncol [Internet] Front. 2022. https:\/\/doi.org\/10.3389\/fonc.2022.898150. [cytowane 6 lipca 2026];12.","journal-title":"Front Oncol [Internet] Front"},{"key":"888_CR15","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/cdd.2014.202","volume":"22","author":"J Farr\u00e9s","year":"2015","unstructured":"Farr\u00e9s J, Llacuna L, Martin-Caballero J, Mart\u00ednez C, Lozano JJ, Ampurdan\u00e9s C, et al. PARP-2 sustains erythropoiesis in mice by limiting replicative stress in erythroid progenitors. Cell Death Differ. 2015;22:1144\u201357. https:\/\/doi.org\/10.1038\/cdd.2014.202.","journal-title":"Cell Death Differ"},{"key":"888_CR16","doi-asserted-by":"publisher","first-page":"898150","DOI":"10.3389\/fonc.2022.898150","volume":"12","author":"R Tashiro","year":"2022","unstructured":"Tashiro R, Kawazoe H, Mamishin K, Seto K, Udagawa R, Saito Y, et al. Patient-associated risk factors for severe anemia in patients with advanced ovarian or breast cancer receiving olaparib monotherapy: A multicenter retrospective study. Front Oncol. 2022;12:898150. https:\/\/doi.org\/10.3389\/fonc.2022.898150.","journal-title":"Front Oncol"},{"key":"888_CR17","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1002\/oby.22294","volume":"26","author":"S Han","year":"2018","unstructured":"Han S, Gan D, Wang G, Ru Y, Huang C, Lin J, et al. Associations of Platelet Indices with Body Fat Mass and Fat Distribution. Obesity (Silver Spring). Silver Spring Md. 2018;26:1637\u201343. https:\/\/doi.org\/10.1002\/oby.22294.","journal-title":"Silver Spring Md"},{"key":"888_CR18","doi-asserted-by":"publisher","first-page":"834153","DOI":"10.1155\/2008\/834153","volume":"2008","author":"D Samocha-Bonet","year":"2008","unstructured":"Samocha-Bonet D, Justo D, Rogowski O, Saar N, Abu-Abeid S, Shenkerman G, et al. Platelet counts and platelet activation markers in obese subjects. Mediators Inflamm. 2008;2008:834153. https:\/\/doi.org\/10.1155\/2008\/834153.","journal-title":"Mediators Inflamm"},{"key":"888_CR19","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.thromres.2022.10.008","volume":"231","author":"A Vauclard","year":"2023","unstructured":"Vauclard A, Bellio M, Valet C, Borret M, Payrastre B, Severin S. Obesity: Effects on bone marrow homeostasis and platelet activation. Thromb Res. 2023;231:195\u2013205. https:\/\/doi.org\/10.1016\/j.thromres.2022.10.008.","journal-title":"Thromb Res"},{"key":"888_CR20","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1080\/09537104.2021.2003317","volume":"33","author":"LJ Goudswaard","year":"2022","unstructured":"Goudswaard LJ, Corbin LJ, Burley KL, Mumford A, Akbari P, Soranzo N, et al. Higher body mass index raises immature platelet count: potential contribution to obesity-related thrombosis. Platelets. 2022;33:869\u201378. https:\/\/doi.org\/10.1080\/09537104.2021.2003317.","journal-title":"Platelets"},{"key":"888_CR21","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1093\/annonc\/mdy181","volume":"29","author":"JS Berek","year":"2018","unstructured":"Berek JS, Matulonis UA, Peen U, Ghatage P, Mahner S, Redondo A, et al. Safety and dose modification for patients receiving niraparib. Ann Oncol. 2018;29:1784\u201392. https:\/\/doi.org\/10.1093\/annonc\/mdy181.","journal-title":"Ann Oncol"},{"key":"888_CR22","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ajcnut.2023.05.002","volume":"118","author":"EA Johnston","year":"2023","unstructured":"Johnston EA, Ibiebele TI, Friedlander ML, Grant PT, van der Pols JC, Webb PM, et al. Association of Protein Intake with Recurrence and Survival Following Primary Treatment of Ovarian Cancer. Am J Clin Nutr. 2023;118:50\u20138. https:\/\/doi.org\/10.1016\/j.ajcnut.2023.05.002.","journal-title":"Am J Clin Nutr"},{"key":"888_CR23","doi-asserted-by":"publisher","first-page":"154267","DOI":"10.1016\/j.prp.2022.154267","volume":"241","author":"D Patel","year":"2023","unstructured":"Patel D, Thankachan S, Sreeram S, Kavitha KP, Suresh PS. The role of tumor-educated platelets in ovarian cancer: A comprehensive review and update. Pathol Res Pract. 2023;241:154267. https:\/\/doi.org\/10.1016\/j.prp.2022.154267.","journal-title":"Pathol Res Pract"},{"key":"888_CR24","doi-asserted-by":"publisher","first-page":"4869","DOI":"10.1182\/blood-2012-06-438598","volume":"120","author":"MS Cho","year":"2012","unstructured":"Cho MS, Bottsford-Miller J, Vasquez HG, Stone R, Zand B, Kroll MH, et al. Platelets increase the proliferation of ovarian cancer cells. Blood. 2012;120:4869\u201372. https:\/\/doi.org\/10.1182\/blood-2012-06-438598.","journal-title":"Blood"},{"key":"888_CR25","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.3390\/cancers16213583","volume":"16","author":"ZR Isingizwe","year":"2024","unstructured":"Isingizwe ZR, Meelheim BA, Benbrook DM. Elevated Platelet Aggregation in Patients with Ovarian Cancer: More than Just Increased Platelet Count. Cancers (Basel). 2024;16:3583. https:\/\/doi.org\/10.3390\/cancers16213583.","journal-title":"Cancers (Basel)"},{"key":"888_CR26","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1110352","volume":"366","author":"RL Stone","year":"2012","unstructured":"Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012;366:610\u20138. https:\/\/doi.org\/10.1056\/NEJMoa1110352.","journal-title":"N Engl J Med"},{"key":"888_CR27","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1182\/blood-2005-01-0160","volume":"106","author":"A Macci\u00f2","year":"2005","unstructured":"Macci\u00f2 A, Madeddu C, Massa D, Mudu MC, Lusso MR, Gramignano G, et al. Hemoglobin levels correlate with interleukin-6 levels in patients with advanced, untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia. Blood. 2005;106:362\u20137. https:\/\/doi.org\/10.1182\/blood-2005-01-0160.","journal-title":"Blood"},{"key":"888_CR28","doi-asserted-by":"publisher","first-page":"10628","DOI":"10.1038\/s41598-024-61015-4","volume":"14","author":"K Ning","year":"2024","unstructured":"Ning K, Sun X, Liu L, He L. Prevalence and contributing factors of anemia in patients with gynecological cancer: a retrospective cohort study. Sci Rep. 2024;14:10628. https:\/\/doi.org\/10.1038\/s41598-024-61015-4.","journal-title":"Sci Rep"},{"key":"888_CR29","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1186\/s12885-022-09887-5","volume":"22","author":"EI Braicu","year":"2022","unstructured":"Braicu EI, Krause CL, Torsten U, Mecke H, Richter R, Hellmeyer L, et al. HE4 as a serum biomarker for the diagnosis of pelvic masses: a prospective, multicenter study in 965 patients. BMC Cancer. 2022;22:831. https:\/\/doi.org\/10.1186\/s12885-022-09887-5.","journal-title":"BMC Cancer"},{"key":"888_CR30","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1373\/clinchem.2010.157073","volume":"57","author":"JM Escudero","year":"2011","unstructured":"Escudero JM, Auge JM, Filella X, Torne A, Pahisa J, Molina R. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. Clin Chem. 2011;57:1534\u201344. https:\/\/doi.org\/10.1373\/clinchem.2010.157073.","journal-title":"Clin Chem"},{"key":"888_CR31","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nm.2989","volume":"19","author":"VS LeBleu","year":"2013","unstructured":"LeBleu VS, Teng Y, O\u2019Connell JT, Charytan D, M\u00fcller GA, M\u00fcller CA, et al. Identification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosis. Nat Med. 2013;19:227\u201331. https:\/\/doi.org\/10.1038\/nm.2989.","journal-title":"Nat Med"},{"key":"888_CR32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/IGC.0000000000000586","volume":"26","author":"G S\u00f6l\u00e9tormos","year":"2016","unstructured":"S\u00f6l\u00e9tormos G, Duffy MJ, Othman Abu Hassan S, Verheijen RHM, Tholander B, Bast RC, et al. Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers. Int J Gynecol Cancer. 2016;26:43\u201351. https:\/\/doi.org\/10.1097\/IGC.0000000000000586.","journal-title":"Int J Gynecol Cancer"},{"key":"888_CR33","first-page":"245","volume":"101","author":"N Osman","year":"2008","unstructured":"Osman N, O\u2019Leary N, Mulcahy E, Barrett N, Wallis F, Hickey K, et al. Correlation of serum CA125 with stage, grade and survival of patients with epithelial ovarian cancer at a single centre. Ir Med J. 2008;101:245\u20137.","journal-title":"Ir Med J"},{"key":"888_CR34","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrclinonc.2009.94","volume":"6","author":"HX Chen","year":"2009","unstructured":"Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol. 2009;6:465\u201377. https:\/\/doi.org\/10.1038\/nrclinonc.2009.94.","journal-title":"Nat Rev Clin Oncol"},{"key":"888_CR35","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484\u201396. https:\/\/doi.org\/10.1056\/NEJMoa1103799.","journal-title":"N Engl J Med"},{"key":"888_CR36","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473\u201383. https:\/\/doi.org\/10.1056\/NEJMoa1104390.","journal-title":"N Engl J Med"},{"key":"888_CR37","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.critrevonc.2013.12.006","volume":"90","author":"GH Lyman","year":"2014","unstructured":"Lyman GH, Abella E, Pettengell R. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review. Crit Rev Oncol Hematol. 2014;90:190\u20139. https:\/\/doi.org\/10.1016\/j.critrevonc.2013.12.006.","journal-title":"Crit Rev Oncol Hematol"},{"key":"888_CR38","doi-asserted-by":"publisher","first-page":"102837","DOI":"10.1016\/j.critrevonc.2019.102837","volume":"145","author":"H Abdel-Razeq","year":"2020","unstructured":"Abdel-Razeq H, Hashem H. Recent update in the pathogenesis and treatment of chemotherapy and cancer induced anemia. Crit Rev Oncol\/Hematol. 2020;145:102837. https:\/\/doi.org\/10.1016\/j.critrevonc.2019.102837.","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"888_CR39","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.6004\/jnccn.2017.0175","volume":"15","author":"J Crawford","year":"2017","unstructured":"Crawford J, Becker PS, Armitage JO, Blayney DW, Chavez J, Curtin P, et al. Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15:1520\u201341. https:\/\/doi.org\/10.6004\/jnccn.2017.0175.","journal-title":"J Natl Compr Canc Netw"},{"key":"888_CR40","doi-asserted-by":"publisher","first-page":"iv96","DOI":"10.1093\/annonc\/mdx758","volume":"29","author":"M Aapro","year":"2018","unstructured":"Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gasc\u00f3n P, Glaspy J, et al. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29:iv96\u2013110. https:\/\/doi.org\/10.1093\/annonc\/mdx758.","journal-title":"Ann Oncol"},{"key":"888_CR41","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1200\/JCO.18.02142","volume":"37","author":"J Bohlius","year":"2019","unstructured":"Bohlius J, Bohlke K, Castelli R, Djulbegovic B, Lustberg MB, Martino M, et al. Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO\/ASH Clinical Practice Guideline Update. J Clin Oncol. 2019;37:1336\u201351. https:\/\/doi.org\/10.1200\/JCO.18.02142.","journal-title":"J Clin Oncol"},{"key":"888_CR42","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1200\/JCO.19.01461","volume":"38","author":"NS Key","year":"2020","unstructured":"Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2020;38:496\u2013520. https:\/\/doi.org\/10.1200\/JCO.19.01461.","journal-title":"J Clin Oncol"},{"key":"888_CR43","doi-asserted-by":"publisher","first-page":"g7594","DOI":"10.1136\/bmj.g7594","volume":"350","author":"GS Collins","year":"2015","unstructured":"Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ. Clin Res ed. 2015;350:g7594. https:\/\/doi.org\/10.1136\/bmj.g7594.","journal-title":"Clin Res ed"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00888-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-026-00888-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-026-00888-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T07:52:58Z","timestamp":1786521178000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-026-00888-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":43,"alternative-id":["888"],"URL":"https:\/\/doi.org\/10.1007\/s43440-026-00888-w","relation":{"references":[{"id-type":"doi","id":"10.3390\/ph18040528","asserted-by":"subject"}]},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"assertion":[{"value":"21 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"During the preparation of this work, the authors used ChatGPT 5.2 to correct readability and style and to ensure that the text is free of errors in grammar, spelling, punctuation, and tone (according to the publisher\u2019s policy). No data or original content was generated with the use of the tool. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the published article.","order":1,"name":"Ethics","label":"Generative AI and AI-assisted technologies in the manuscript preparation process","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Miko\u0142aj Piotr Zaborowski, MD, PhD, reports speaking fees, lecture honoraria, and travel reimbursements from GlaxoSmithKline, AbbVie, AstraZeneca, and MSD. The remaining authors declare that they have no competing interests.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}